Clinical Trial Detail

NCT ID NCT02924038
Title A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, San Francisco
Indications

astrocytoma

oligodendroglioma

malignant glioma

Therapies

IMA950 + Poly ICLC

Varlilumab

Age Groups: senior adult

No variant requirements are available.